Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2770310 | 0.89 | PTGDR2 (0.54) | PTGDR2PTGS2PTGS1HSP90AA1 | |
| SCHEMBL3569757 | 0.89 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL2770749 | 0.89 | PTGDR2 (0.42) | PTGDR2PTGS2PTGS1 | |
| SCHEMBL3564308 | 0.87 | PTGS2 (0.40) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2770081 | 0.81 | PTGDR2 (0.46) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2769893 | 0.81 | PTGDR2 (0.44) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2774837 | 0.80 | PTGDR2 (0.40) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2772075 | 0.80 | PTGDR2 (0.38) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2769682 | 0.79 | L3MBTL1 (0.41) | PTGDR2PTGS2PTGS1ALDH1A1 | |
| SCHEMBL2771396 | 0.79 | PTGDR2 (0.50) | PTGDR2PTGS2PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | PTGDR2 167/4885PTGS2 426/4885PTGS1 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.